Scholarlink

Purpose <p>We aimed to describe treatment patterns of patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) who progressed after receiving darolutamide in a real-world setting, and according to the standard clinical practice in Spain.</p> Methods <p>This was a multicenter, observational, retrospective study conducted at the urology and oncology departments of 17 Spanish hospitals that participated in the ARAMIS trial and its rollover study.</p> Results <p>85 patients, with a median age of 76&#xa0;years, were included in the study. 49 patients (57.6%) progressed to mCRPC, with metastases located mainly in bone. Only 35 of them (71.4%) received at least one subsequent therapy. The most common first-line treatments after darolutamide were abiraterone (<i>n</i> = 22, 63%) and docetaxel (<i>n</i> = 10, 29%), with a median (IQR) treatment duration of 7.6&#xa0;months (4.7, 12.7) and 4.8&#xa0;months (3.8, 5.8), respectively; besides, the most frequent first-line/second-line treatment sequences were abiraterone–docetaxel and docetaxel–cabazitaxel. In addition, only 20% of patients with bone metastases received osteoclast-targeted therapy.</p> Conclusion <p>These real-world practice patterns suggest a lack of consensus in Spanish clinical practice for the management of patients with mCRPC, indicating that there is a need for more standardized strategies and unification of the criteria to make decisions in accordance with the recommendations of international clinical practice guidelines.</p> Clinical trial registration <p>Not applicable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Treatment patterns in patients with castration-resistant prostate cancer who received darolutamide in the ARAMIS trial in Spain: PARASEC study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月10日

查看全文
  • Javier Puente,
  • Rubén Campanario,
  • David Marmolejo,
  • Juan Andrés Cantero-Mellado,
  • Álvaro Gómez-Ferrer,
  • Alfredo Rodríguez Antolín,
  • María J. Ribal,
  • Natalia Picola Brau,
  • María José Ledo,
  • Carlos Hernandez,
  • Carlos Llorente,
  • Carmen González-Enguita,
  • Álvaro Bisonó Castillo,
  • Joan Benejam,
  • Jesús Gil Guijarro,
  • Jose Garcia-Sanchez,
  • Joan Folqué,
  • Javier Casas-Nebra

摘要

Purpose

We aimed to describe treatment patterns of patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) who progressed after receiving darolutamide in a real-world setting, and according to the standard clinical practice in Spain.

Methods

This was a multicenter, observational, retrospective study conducted at the urology and oncology departments of 17 Spanish hospitals that participated in the ARAMIS trial and its rollover study.

Results

85 patients, with a median age of 76 years, were included in the study. 49 patients (57.6%) progressed to mCRPC, with metastases located mainly in bone. Only 35 of them (71.4%) received at least one subsequent therapy. The most common first-line treatments after darolutamide were abiraterone (n = 22, 63%) and docetaxel (n = 10, 29%), with a median (IQR) treatment duration of 7.6 months (4.7, 12.7) and 4.8 months (3.8, 5.8), respectively; besides, the most frequent first-line/second-line treatment sequences were abiraterone–docetaxel and docetaxel–cabazitaxel. In addition, only 20% of patients with bone metastases received osteoclast-targeted therapy.

Conclusion

These real-world practice patterns suggest a lack of consensus in Spanish clinical practice for the management of patients with mCRPC, indicating that there is a need for more standardized strategies and unification of the criteria to make decisions in accordance with the recommendations of international clinical practice guidelines.

Clinical trial registration

Not applicable.